{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:24:56Z","timestamp":1789856696519,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clim.2017.09.002","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T17:16:18Z","timestamp":1504545378000},"page":"167-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade"],"prefix":"10.1016","volume":"183","author":[{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-4544","authenticated-orcid":false,"given":"Carmen","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Rosskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard J.","family":"Zlabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.09.002_bb0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.187.9.1383","article-title":"Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes","volume":"187","author":"Gallimore","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0010","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0015","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clim.2017.09.002_bb0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","volume":"479-480","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.clim.2017.09.002_bb0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clim.2017.09.002_bb0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment","volume":"56","author":"Grabmeier-Pfistershammer","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.clim.2017.09.002_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0045","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.09.002_bb0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clim.2017.09.002_bb0055","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0060","doi-asserted-by":"crossref","first-page":"e1003253","DOI":"10.1371\/journal.ppat.1003253","article-title":"TIM-3 does not act as a receptor for galectin-9","volume":"9","author":"Leitner","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2017.09.002_bb0065","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1","volume":"75","author":"Hezareh","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2017.09.002_bb0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3389\/fimmu.2017.00572","article-title":"PD-1 blockade promotes emerging checkpoint inhibitors in enhancing T cell responses to allogeneic dendritic cells","volume":"8","author":"Stecher","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0075","doi-asserted-by":"crossref","first-page":"e30307","DOI":"10.1371\/journal.pone.0030307","article-title":"HIV-induced T-cell activation\/exhaustion in rectal mucosa is controlled only partially by antiretroviral treatment","volume":"7","author":"Rueda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.09.002_bb0080","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4049\/jimmunol.0902781","article-title":"Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1","volume":"184","author":"Salisch","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0085","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.4049\/jimmunol.1200646","article-title":"Programmed death-1 is a marker for abnormal distribution of naive\/memory T cell subsets in HIV-1 infection","volume":"191","author":"Breton","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0090","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.7448\/IAS.19.1.20697","article-title":"Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era","volume":"19","author":"Cao","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.clim.2017.09.002_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-407707-2.00002-3","article-title":"Residual immune dysregulation syndrome in treated HIV infection","volume":"119","author":"Lederman","year":"2013","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2010-12-328070","article-title":"Responsiveness of HIV-specific CD4 T cells to PD-1 blockade","volume":"118","author":"Porichis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.09.002_bb0105","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4049\/jimmunol.1102610","article-title":"Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation","volume":"188","author":"Janbazian","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0110","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.09.002_bb0115","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.09.002_bb0120","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2017.09.002_bb0125","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0130","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2017.09.002_bb0135","doi-asserted-by":"crossref","first-page":"e0140694","DOI":"10.1371\/journal.pone.0140694","article-title":"TIM-3 suppresses anti-CD3\/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway","volume":"10","author":"Tomkowicz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.09.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2012.01.012","article-title":"Down-regulation of interleukin-2 production by CD4(+) T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription","author":"Lee","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.clim.2017.09.002_bb0145","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.clim.2017.09.002_bb0150","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0155","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.clim.2017.09.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040146","article-title":"Tim-3 negatively regulates cytotoxicity in exhausted CD8(+) T cells in HIV infection","volume":"7","author":"Sakhdari","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.09.002_bb0165","first-page":"693","article-title":"Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway","volume":"24","author":"Wu","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.clim.2017.09.002_bb0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1172\/JCI40070","article-title":"BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination","volume":"120","author":"Derre","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2017.09.002_bb0175","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","article-title":"CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1","volume":"72","author":"Fourcade","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2017.09.002_bb0180","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.4049\/jimmunol.0902487","article-title":"B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function","volume":"185","author":"Serriari","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.09.002_bb0185","doi-asserted-by":"crossref","first-page":"e1002840","DOI":"10.1371\/journal.ppat.1002840","article-title":"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction","volume":"8","author":"Peretz","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.clim.2017.09.002_bb0190","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0195","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0200","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clim.2017.09.002_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.09.002_bb0210","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617305065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617305065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:59:34Z","timestamp":1761494374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617305065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":42,"alternative-id":["S1521661617305065"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.09.002","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}